These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 18839776)

  • 41. From trials to a real hospital setting: effectiveness of pegylated interferon-alpha-2b/ribavirin combination therapy for naïve chronic hepatitis C patients.
    Piai G; Scalice E; Focareta R; Terracciano F; de Filippo FR; Forte G
    Dig Dis Sci; 2006 Sep; 51(9):1619-26. PubMed ID: 16927136
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pegylated IFN-alpha2b plus ribavirin for treatment-naive patients coinfected with HCV and HIV.
    Mallolas J; Laguno M
    Expert Rev Anti Infect Ther; 2008 Jun; 6(3):281-9. PubMed ID: 18588492
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Investigational drugs for hepatitis C.
    Flisiak R; Parfieniuk A
    Expert Opin Investig Drugs; 2010 Jan; 19(1):63-75. PubMed ID: 20001555
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanisms of non-response to antiviral treatment in chronic hepatitis C.
    Chevaliez S; Asselah T
    Clin Res Hepatol Gastroenterol; 2011 Jun; 35 Suppl 1():S31-41. PubMed ID: 21742299
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current progress in the treatment of chronic hepatitis C.
    Alexopoulou A; Papatheodoridis GV
    World J Gastroenterol; 2012 Nov; 18(42):6060-9. PubMed ID: 23155334
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interferon-based therapy for chronic hepatitis C: current and future perspectives.
    Zeuzem S
    Nat Clin Pract Gastroenterol Hepatol; 2008 Nov; 5(11):610-22. PubMed ID: 18838975
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history.
    Degasperi E; Viganò M; Aghemo A; Lampertico P; Colombo M
    Expert Rev Anti Infect Ther; 2013 May; 11(5):459-74. PubMed ID: 23627852
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection.
    Tsantrizos YS
    Curr Opin Investig Drugs; 2009 Aug; 10(8):871-81. PubMed ID: 19649931
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action.
    Paeshuyse J; Dallmeier K; Neyts J
    Curr Opin Virol; 2011 Dec; 1(6):590-8. PubMed ID: 22440916
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A review of current anti-HCV treatment regimens and possible future strategies.
    Neukam K; Macías J; Mira JA; Pineda JA
    Expert Opin Pharmacother; 2009 Feb; 10(3):417-33. PubMed ID: 19191679
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors.
    Naggie S; Patel K; McHutchison J
    J Antimicrob Chemother; 2010 Oct; 65(10):2063-9. PubMed ID: 20688770
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A hepatitis C viral kinetic model that allows for time-varying drug effectiveness.
    Shudo E; Ribeiro RM; Talal AH; Perelson AS
    Antivir Ther; 2008; 13(7):919-26. PubMed ID: 19043926
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [HCV entry as a new therapeutic target in chronic hepatitis C].
    Dabrowska MM; Panasiuk A; Flisiak R
    Pol Merkur Lekarski; 2009 Aug; 27(158):140-3. PubMed ID: 19856882
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety of small molecules in combination with interferon-based therapy for hepatitis C virus.
    Rustgi VK
    Expert Opin Drug Saf; 2010 Nov; 9(6):883-92. PubMed ID: 20553105
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C.
    Vrolijk JM; Kaul A; Hansen BE; Lohmann V; Haagmans BL; Schalm SW; Bartenschlager R
    J Virol Methods; 2003 Jun; 110(2):201-9. PubMed ID: 12798249
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New therapies for the treatment of chronic hepatitis C.
    Idéo G; Bellobuono A
    Curr Pharm Des; 2002; 8(11):959-66. PubMed ID: 11945142
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of hepatitis C: how will we use viral kinetics, response-guided therapy?
    Pawlotsky JM
    Curr Gastroenterol Rep; 2013 Feb; 15(2):309. PubMed ID: 23314805
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C.
    Hügle T; Cerny A
    Rev Med Virol; 2003; 13(6):361-71. PubMed ID: 14625884
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals.
    Coppola N; Pisaturo M; Zampino R; Macera M; Sagnelli C; Sagnelli E
    World J Gastroenterol; 2015 Oct; 21(38):10749-59. PubMed ID: 26478667
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Inhibitors of hepatitis C virus--current standards and status of investigations].
    Godzik P; Komorowski M; Cielecka-Kuszyk J; Madaliński K
    Przegl Epidemiol; 2010; 64(4):473-8. PubMed ID: 21473060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.